<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03465410</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMUS</org_study_id>
    <nct_id>NCT03465410</nct_id>
  </id_info>
  <brief_title>OPTImization of the Dose of tacroliMUS by Bayesian Prediction</brief_title>
  <acronym>OPTIMUS</acronym>
  <official_title>OPTIMIZATION of the Dose of tacroliMUS by Bayesian Prediction in Renal Transplant Patients Including Pharmacogenetic Variables</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NURIA LLOBERAS BLANCH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of tacrolimus (TAC) are characterized by high inter- and&#xD;
      intra-individual variability with narrow therapeutic range. Currently, the limiting point of&#xD;
      Tac drug monitoring is the inability to individualize doses during the first few days after&#xD;
      transplantation. Our group developed a population pharmacokinetic model (PPK) identifying&#xD;
      CYP3A4 * 22 and CYP3A5 * 3 polymorphisms and hematocrit as explanatory variables of the&#xD;
      observed variability in pre-dose (Co) concentrations. According to this model, the proportion&#xD;
      of patients that do not reach the therapeutic target is 40&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The results of the study of genetic polymorphisms performed in renal transplant patients at&#xD;
      our hospital demonstrated the influence of CYP3A5 * 3 and CYP3A4 * 22 single nucleotide&#xD;
      polymorphism (SNPs) on exposure to Tac. From these results, the first population&#xD;
      pharmacokinetic model was developed, which included CYP3A5 * 3 and CYP3A4 * 22 polymorphisms&#xD;
      as well as hematocrit as explanatory variables of interindividual variability. Based on our&#xD;
      population model and using the simulation tool, the percentage of patients reaching the&#xD;
      therapeutic target based on Co values within the range of 6-10 ng / mL was determined after&#xD;
      being dosed according to the strategy of Conventional dosage empirically according to Co&#xD;
      achieved. The simulation of 50 Co values according to the conventional dosage allowed to&#xD;
      determine the proportion of patients reaching the therapeutic target in each case and their&#xD;
      confidence interval. 40% of the patients did not reach the therapeutic objective. Based on&#xD;
      the clusters of the two polymorphisms, the percentages of patients on or below exposed varied&#xD;
      according to whether they were slow or fast metabolizers respectively. Due to this high&#xD;
      variability in Tac PK, the individualization of the Tac posology was calculated by&#xD;
      calculating the initial dose according to the population model previously developed and&#xD;
      adjusting the subsequent doses, as a function of the Tac Co through Bayesian approximations&#xD;
      with the inclusion of genotyping and Hematocrit, can contribute greatly to achieve optimal&#xD;
      exposure to the drug from the start of treatment in the immediate post-transplant and reduce&#xD;
      the variability observed in the Co-achieved; This may be particularly important for patients&#xD;
      with a slow and rapid metabolizer profile. All of this may contribute to minimizing adverse&#xD;
      effects, ensuring greater efficacy in the target population, reducing the risk of acute&#xD;
      rejection, and reducing associated costs.&#xD;
&#xD;
      In the present study we intend to incorporate pharmacogenomics for its application in de novo&#xD;
      patients, which will allow us to perform a more individualized therapy for each patient based&#xD;
      on the values of target Co and the CYP3A5 * 3 and CYP3 A4 * 22 polymorphisms of the patient&#xD;
      since The initiation of immunosuppressive therapy and thus improve efficiency and decrease&#xD;
      adverse effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Actual">September 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 21, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, prospective, multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus plasmatic concentrations measurement</measure>
    <time_frame>Day 6, 10, 15, 30, 60 and 90 post transplant</time_frame>
    <description>Concentration measured at day 6, 10, 15, 30, 60 and 90 post transplant and after each Tacrolimus dose adjustment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Tacrolimus therapeutic target levels</measure>
    <time_frame>90 days</time_frame>
    <description>Time to achieve Tacrolimus therapeutic target levels within the 90 days post transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tacrolimus dose changes to achieve target levels</measure>
    <time_frame>90 days</time_frame>
    <description>Number of Tacrolimus dose changes to achieve target levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>KIDNEY TRANSPLANTATION</condition>
  <arm_group>
    <arm_group_label>GROUP I Standard adjustment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dosage of Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP II Bayesian prediction adjustment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bayesian prediction Tacrolimus dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard dosage of Tacrolimus</intervention_name>
    <description>Immediate release Tacrolimus (Prograf/Adoport)</description>
    <arm_group_label>GROUP I Standard adjustment</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bayesian Prediction Tacrolimus dosage</intervention_name>
    <description>Immediate release Tacrolimus (Prograf/Adoport)</description>
    <arm_group_label>GROUP II Bayesian prediction adjustment</arm_group_label>
    <other_name>Tacrolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant recipients, from cadaveric and living donor.&#xD;
&#xD;
          -  Patients that are going to receive immediate release Tacrolimus (Prograf/Adoport) as&#xD;
             part of immunosuppressive treatment.&#xD;
&#xD;
          -  Concomitant immunosuppression with Mycophenolate mofetil/Mycophenolic acid and&#xD;
             steroids.&#xD;
&#xD;
          -  Induction with Basiliximab is permitted.&#xD;
&#xD;
          -  Subjects able to provide written informed consent.&#xD;
&#xD;
          -  Female subjects of child-bearing potential must have a negative serum pregnancy test&#xD;
             and must be practicing an effective, reliable, and medically approved contraceptive&#xD;
             regimen during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects treated with drugs that can potentially interfere with Tacrolimus, especially&#xD;
             CYP3A4 inhibitors (telaprevir, boceprevir, ritonavir, ketoconazole, voriconazole,&#xD;
             itraconazole, telithromycin or clarithromycin) or CYP3A4 inductors (rifampicin or&#xD;
             rifabutine).&#xD;
&#xD;
          -  Subjects that receive induction treatment with Thymoglobulin or rituximab.&#xD;
&#xD;
          -  Subjects participating in another investigational study within 30 days before&#xD;
             inclusion.&#xD;
&#xD;
          -  Subjects with hepatopathy.&#xD;
&#xD;
          -  Subject or donor with a history of any malignancy (within the past 5 years), except&#xD;
             non-metastatic basal or squamous cell carcinoma of the skin .&#xD;
&#xD;
          -  Female subjects who are pregnant or breast feeding.&#xD;
&#xD;
          -  Subjects receiving an ABO incompatible kidney.&#xD;
&#xD;
          -  Subjects have Donor Specific Antibodies.&#xD;
&#xD;
          -  Recipients of an allograft with ischemic cold time &gt; or = 24 hours.&#xD;
&#xD;
          -  Subjects with a history of active hepatitis C virus (HCV-RNA positive) and/or&#xD;
             hepatitis B virus (DNA-HBV or HBsAg positive) infection.&#xD;
&#xD;
          -  Subjects with a history of human immunodeficiency virus (HIV-Ab positive) infection.&#xD;
&#xD;
          -  Subjects with psychiatric or physical illness that could interfere with the ability of&#xD;
             the subject to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NÃºria Lloberas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>NURIA LLOBERAS BLANCH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

